A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Clinicians use drug detoxification to reduce or relieve withdrawal symptoms while helping an addicted person adjust to living without drug use. Drug detoxification does not aim to treat addiction but rather represents an early step within long-term treatment. Detoxification may be achieved drug-free or may use medications as an aspect of treatment. Often drug detoxification and treatment will occur in a community program that lasts several months and takes place in a residential setting rather than in a medical center. Drug detoxification varies depending on the location of treatment, but most detox centers provide treatment to avoid the symptoms of physical withdrawal from alcohol and from other drugs. Most also incorporate counseling and therapy during detox to help with the consequences of withdrawal.
=== Tolerance === Mescaline is associated with rapid tolerance development, including cross-tolerance with other psychedelics like LSD and psilocybin. This tolerance is apparent within a few days and resets after 3 or 4 days of abstinence.
=== Designed proteins === Numerous protein structures are the result of rational design and do not exist in nature. Proteins can be designed from scratch (de novo design) or by making calculated variations on a known protein structure and its sequence (known as protein redesign). Rational protein design approaches make protein-sequence predictions that will fold to specific structures. These predicted sequences can then be validated experimentally through methods such as peptide synthesis, site-directed mutagenesis, or Artificial gene synthesis.
Sources: en.wikipedia.org
The player's main method of defeating guests is with Combat pages, items used to attack and defend in combat through predetermined actions. The number of Combat Pages usable in a single Scene is equal to the number of Speed Dice a character has. Attacks deal both physical and stagger damage, affecting characters' HP and SR respectively. If a character's SR reaches zero, they will be unable to move and receive fatal damage from all attacks until their SR resets the next turn. A character dies (for the ongoing reception) if their HP reaches 0. Upon starting the Scene, all characters' Speed dice will randomly roll a low or high number or value, determining its Speed and the order of characters' actions. Librarians can redirect Combat pages towards them if they possess higher Speed than their target. Most characters (except bosses) start a reception with 1 or 2 Speed dice. If a librarian redirects a Combat page or opposes a Combat page directed at them, they enter a clash where both sides' Combat pages' actions interact with each other. Two dice will roll and the highest value will act; if both dice roll the same value, actions will be canceled out. Else, the attack counts as a one-sided action where attacks are not opposed. The player needs to carefully manage available resources, namely 'Light' (a form of combat stamina) and Combat pages, which return into the deck to be randomly picked upon usage. If the librarian's current Light is lower than the cost of any available Combat page, or if the librarian has no Combat pages to initiate action, they will be unable to act.
Nitrogenous fertilizers tend to create acidic conditions, which are fatal to the worms, and dead specimens are often found on the surface following the application of various pesticides, among which insecticides and fungicides are the most toxic. In Australia, changes in farming practices such as the application of superphosphates on pastures and a switch from pastoral farming to arable farming had a devastating effect on populations of the giant Gippsland earthworm Megascolides australis, leading to their classification as a protected species. Globally, certain earthworm populations have been devastated by deviation from organic production and the spraying of synthetic fertilizers and biocides, with at least three species now listed as extinct, but many more endangered.
== Overview == Trails is a series of role-playing video games by Nihon Falcom set in a science fantasy universe. It began as the sixth entry in Falcom's The Legend of Heroes franchise with the release of The Legend of Heroes VI: Trails in the Sky in 2004. Despite that, it had no narrative connection with prior Legend of Heroes games and is considered its own distinct franchise. The Trails games are set within a few years of each other and follow an overarching narrative, with the events of a few entries crossing over into another. The series was conceived by Falcom to have the most ambitious story in video games, with company president and series producer Toshihiro Kondo considering it to be his life's work. The games are made using a proprietary game engine known as the Falcom Developer Kit (FDK), with the exception being Sony's PhyreEngine used for the Trails of Cold Steel games and Trails into Reverie. The series is heavily influenced by anime and features several archetypes and tropes common to it. Trails is set across several locations on the continent of Zemuria, such as the Liberl Kingdom, the city-state of Crossbell, the Erebonian Empire, and the Calvard Republic, among others. Zemuria is home to several groups, factions, and organizations, such as the Bracer's Guild, the Septian Church, the secret society of Ouroboros, mercenary groups known as Jaegers, and several more. The series is set half a century after the discovery of orbal energy, an analog to electric power.
Sources: en.wikipedia.org
== Bibliography == J. Samuel Walker (November 1, 2000). Permissible Dose: A History of Radiation Protection in the Twentieth Century. University of California Press. ISBN 978-0-520-92484-0. Limited preview in Google Books. K. N. Govinda Rajan (July 28, 2017). Radiation Safety in Radiation Oncology. CRC Press. ISBN 978-1-4987-6226-7. Limited preview in Google Books. Strahlengefahrdung und Strahlenschutz / Radiation Exposure and Radiation Protection. Springer-Publisher. March 13, 2013. ISBN 978-3-642-82229-2. Limited preview in Google Books J. Samuel Walker (April 2001). Short History of Nuclear Regulation, 1946–1999. DIANE Publishing. ISBN 978-0-7567-0929-7.Limited preview in Google Books. Ashley W. Oughterson, Shields Warren: Medical Effects of the Atomic Bomb in Japan. Volume VIII.8 aus der National Nuclear Energy Series zum Manhattan Project, McGraw-Hill Book Company, 1956. Carl Voegtlin, Harold C. Hodge: Pharmacology and Toxicology of Uranium Compounds. Volume VI.1, Part I and Part II (with a Section on the Pharmacology and Toxicology of Fluorine and Hydrogen Fluoride) from the National Nuclear Energy Series to the Manhattan Project, McGraw-Hill Book Company, 1949. Henry DeWolf Smyth (written on the request of Maj. Gen. L. R. Groves): Atomic Energy for Military Purposes. The official report on the development of the atomic bomb under the auspices of the United States Government, 1940–1945. Princeton University Press, 1946. James E. Grindler (Argonne National Laboratory): The Radiochemistry of Uranium.
==== Drug delivery ==== Emerging methods of drug delivery involving nanotechnological methods can be useful by improving bodily response, specific targeting, and non-toxic metabolism. Many nanotechnological methods and materials can be functionalized for drug delivery. Ideal materials employ a controlled-activation nanomaterial to carry a drug cargo into the body. Mesoporous silica nanoparticles (MSN) have increased in research popularity due to their large surface area and flexibility for various individual modifications while maintaining high-resolution performance under imaging techniques. Activation methods greatly vary across nanoscale drug delivery molecules, but the most commonly used activation method uses specific wavelengths of light to release the cargo. Nanovalve-controlled cargo release uses low-intensity light and plasmonic heating to release the cargo in a variation of MSN containing gold molecules. The two-photon activated photo-transducer (2-NPT) uses near infrared wavelengths of light to induce the breaking of a disulfide bond to release the cargo. Recently, nanodiamonds have demonstrated potential in drug delivery due to non-toxicity, spontaneous absorption through the skin, and the ability to enter the blood–brain barrier. The unique structure of carbon nanotubes also gives rise to many innovative inventions of new medical methods. As more medicine is made at the nano level to revolutionize the ways for human to detect and treat diseases, carbon nanotubes become a stronger candidate in new detection methods and therapeutic strategies.
=== United States === In the 2 July 2026 issue of Federal Register (21 FR 1308), the federal government of the United States issued a notice of intent to publish a temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16) under Schedule I of the Controlled Substances Act. If issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances. on August 26 of 2026 the federal government placed all three of the above mentioned chemicals under schedule 1. That will remain in effect for two years. This forbids most all use and research and possession of these chemicals.
== Mechanism == Carfilzomib covalently irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme that degrades unwanted cellular proteins. Carfilzomib displays minimal interactions with non-proteasomal targets, thereby improving safety profiles over bortezomib. Inhibition of proteasome-mediated proteolysis results in a build-up of polyubiquitinated proteins, which may cause cell cycle arrest, apoptosis, and inhibition of tumor growth.
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.